Bilcare P/E Ratio
Current P/E Ratio
138.88
High Valuation
Very High - High growth expectations or significantly overvalued
Bilcare P/E ratio. Bilcare (BI) P/E ratio is 138.88 (High), EPS (TTM) ₹0.73, current price ₹101.38 on NSE — Very High - High growth expectations or significantly overvalued. Examine BI earnings for recent quarterly revenue, profit and EPS trends.
Current Valuation Metrics
P/E Ratio
138.88
Current Price
₹101.38
EPS (TTM)
₹0.73
Exchange
NSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
56.19
Sector Median
32.5
Sector Rank
#11 of 200
Sector Percentile
5.5%
Earnings Breakdown (TTM)
TTM EPS
₹13.29
Mar 2026
₹5.68
Jun 2026
₹5.39
BI P/E Ratio — Valuation Signal & Historical Context
Bilcare P/E 138.88 — signal: Overvalued. For live price, revenue and the complete fundamental profile, see Bilcare screener.
- Stock appears overvalued with PE of 138.88, suggesting caution for new investments
- Trading at premium to sector average PE of 56.19
BI vs Healthcare Peers — P/E Ratio Comparison
Bilcare P/E 138.88 vs Healthcare average 56.19, median 32.5 — range 2.04–740.29.
Sector Average
56.19
Sector Median
32.5
Lowest P/E
2.04
Highest P/E
740.29
Companies
200
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.04 | ₹65 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹63 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.98 | ₹6,206 | Low |
| Dipna Pharmachem | DPL | 4.57 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.88 | ₹66 | Low |
| GKB Ophthalmics | GKB | 5.88 | ₹32 | Low |
| Kabra Drugs | KABRADG | 6.09 | ₹44 | Low |
| Royal Sense | ROYAL | 6.58 | ₹47 | Low |
| Colinz Laboratories | COLINZ | 6.62 | ₹18 | Low |